Phase I-II study of XXXX in @entity1582 .

@entity1 @entity632 @entity1665 @entity137 @entity390 @entity3136 @entity712 @entity4349 @entity1259 @entity391 @entity1582 @entity1398 @entity583 @entity221
Forty @entity1 with relapsed (26) or refractory (14) @entity1582 were treated with @entity1259 of doses of 75, 90, 105, and 120 mg/m2 in groups of 6 or more @entity1 to test for response, maximum tolerated dose, and @entity137 . Thirteen @entity1 had received prior @entity632 and were included in the dose findings part of the study only. Staging was I (1), II (5), and III (34). Partial responses were seen in 5 @entity1 (18.5%) (duration 1.5, 2, 2.5, 10, and 18 months) not previously treated with @entity632 . No responses were seen in @entity1 treated with prior @entity4349 . Responses were not dependent upon dose level of @entity1259 . Median nadir white blood cell count at the four-dose levels were 2,300, 1,000, 1,600, and 1,700/mm3 with median nadir granulocyte counts of 897, 720, 688, and 192/mm3. @entity221 / @entity1398 was infrequently observed at the three lower dose levels but occurred in 6 of 10 @entity1 at 120 mg/m2. Platelet nadirs were 110,000, 83,000, 169,000, and 42,000/mm3. Nonhematological @entity137 was not dose dependent and included @entity1665 (100%), @entity390 / @entity391 (40%), and @entity3136 (25%). Six @entity1 had greater than or equal to 0.10 changes in the resting ejection fraction with one @entity1 developing @entity712 that responded to medical management. This @entity1 had received prior @entity632 and had a history of @entity583 . @entity1259 can produce remissions in @entity1 with previously treated @entity1582 who have not received prior @entity632 . Since the response rate was not enhanced at 120/m2 and since @entity221 / @entity1398 was seen regularly at this dose level, the recommended dose for further study is 105 mg/m2.
